Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim
“As the HIV community mourns the loss of Dr. Krim, we at Napo would like
to recognize her immense contributions to the fight against HIV. Dr.
Krim leaves a long legacy that will continue onward with the work of
amfAR and within the generations that stem from those whose lives she
Dr. Krim, a geneticist and virologist, carved a long and prestigious history of battling HIV as a scientist, a human rights activist, philanthropist and educator. Dr. Krim passionately fought for the rights and anti-stigmatization of people living with HIV, for legislation regarding expanded access to lifesaving treatment, for the development of sound, AIDS-related public policies, and ethical HIV treatment and prevention research.
In 1983, to raise funds for AIDS research, Dr. Krim and others founded
Over the past 34 years, amfAR has invested over
amfAR’s research initiatives have helped advance our understanding and
progress on HIV treatment, prevention, and epidemiology and greatly
contributed to the development of several new classes of antivirals,
including Fusion Inhibitors and CC5 antagonists. amfAR’s early studies
of protease inhibitors helped to revolutionize HIV treatment, resulting
in transforming HIV/AIDS into a treatable disease. amfAR continues to
financially support prevention research to lessen the impact of HIV to
the MSM and transgender communities; support the safe and effective
delivery of HIV treatments in the
Dr. Krim received her Ph.D. in
Jaguar Health, Inc.